MannKind's inhaled nintedanib trial meets primary safety goal in IPF

July 29, 2026 6:30 AM

MannKind Corporation (Nasdaq: MNKD) announced positive topline results from INFLO-1, its Phase 1b clinical study evaluating an inhaled dry powder ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found